Molecular Partners To Cut Up To 40 Jobs In Strategic Review, Extends Cash Runway Into 2028

Benzinga · 06/10 05:48
- Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025
- Cash reach now anticipated to extend into 2028
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.